T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors

"Dosing Schedule 1:~Cycle 1 A: 1x10\^7 cells~Cycle 2 A: 1x10\^7 cells~Cycle 3 A: 1x10\^7 cells~Dosing Schedule 2:~Cycle 1 A: 1x10\^7 cells~Cycle 2 B: 3x10\^7 cells~Cycle 3 B: 3x10\^7 cells~Dosing Schedule 3:~Cycle 1 A: 1x10\^7 cells~Cycle 2 B: 3x10\^7 cells~Cycle 3 C: 1x10\^8 cells~Subsequent cycles\*~\*Additional cycles may be administered at ≤ the final cell dose reached in cycle 3, provided that the subject continues to meet eligibility criteria and does not have confirmed progressive disease."